Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
For full access to this article login to GEN Select now.
BioMarket Trends: Orphan Drug Arena Driven by Biologics
Entry of Biogenerics Will Radically Alter Market that Is Mainstay of Some Biotech Firms
- An orphan drug can be defined as a product that treats a rare disease, although different countries have slightly different definitions. For example, the FDA defines a rare disease as a disease with an incidence of less than 1:5,000 of the general population, while the European Union defines it ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.